A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

NCT06788431 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: IMC-001 and Optimal medical treatment
DRUG: IMC-001 placebo and optimal medical treatment

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Collaborators

[object Object]
[object Object]
[object Object]